S&W client, the UK Markey Cancer Foundation, recently received a $1 million gift from the Amanda W. Lockey Foundation to create the world’s first distinguished professorship in neuroendocrine tumor (NET) research. This donation will support Lowell Anthony, M.D., a celebrated medical oncologist, in his clinical and translational research as well as in the development of a radiotherapeutic program. According to Anthony, “This generous gift is recognition of our expertise in neuroendocrine tumors and will allow the center to advance our understanding of NET biology. The NET professorship provides additional resources to support our growth in translational NET research and making Markey cutting edge with this technology.”
Currently, the UK Markey Cancer Center has the most NET Radiopharmaceutical Therapy Program (RPT) clinical trials open at a single center in the United States. The groundbreaking treatments being developed and tested by Dr. Anthony and his team have been crucial in extending both the duration and quality of life in patients with neuroendocrine tumors.
“The UK Markey Cancer Center was so fortunate to obtain such a high-level recruit in Dr. Anthony from LSU,” said Michael Delzotti, Markey Cancer Foundation president & CEO. “He is an internationally recognized NET researcher and physician-scientist. This generous philanthropic support by the Lockey Foundation will further accelerate the life-saving and cutting-edge research he is doing at Markey.”
This gift comes as part of a campaign in support of UK Markey’s application for obtaining National Cancer Institute (NCI) Comprehensive Cancer Center status, the highest designation a cancer center can receive. As a trusted partner of the UK Markey Cancer Foundation, we are excited to see how this gift furthers the fight against cancer in Kentucky.